Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $9.28 in the prior trading day, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $9.00, down -3.02%. In other words, the price has decreased by -$3.02 from its previous closing price. On the day, 28.39 million shares were traded.
Ratios:
Our goal is to gain a better understanding of RXRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.35. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 06 ’25 when Gibson Christopher sold 20,000 shares for $8.12 per share. The transaction valued at 162,400 led to the insider holds 1,273,156 shares of the business.
Gibson Christopher sold 20,000 shares of RXRX for $153,600 on Feb 05 ’25. The Chief Executive Officer now owns 1,273,156 shares after completing the transaction at $7.68 per share. On Feb 06 ’25, another insider, Gibson Christopher, who serves as the Officer of the company, bought 20,000 shares for $8.12 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 53.96 while its Price-to-Book (P/B) ratio in mrq is 4.91.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is 19.12%, while the 200-Day Moving Average is calculated to be 20.38%.
Shares Statistics:
A total of 390.76M shares are outstanding, with a floating share count of 297.00M. Insiders hold about 23.99% of the company’s shares, while institutions hold 61.89% stake in the company.
Earnings Estimates
A detailed examination of Recursion Pharmaceuticals Inc (RXRX) is currently in progress, with 7.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.34 and low estimates of -$0.8.
Analysts are recommending an EPS of between -$1.22 and -$1.9 for the fiscal current year, implying an average EPS of -$1.54. EPS for the following year is -$1.64, with 9.0 analysts recommending between -$1.28 and -$2.9.
Revenue Estimates
7 analysts predict $19.04M in revenue for the current quarter. It ranges from a high estimate of $40.1M to a low estimate of $8M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $10.89MFor the next quarter, 7 analysts are estimating revenue of $12M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $6M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $94.3M, while the lowest revenue estimate was $44.61M, resulting in an average revenue estimate of $67.8M. In the same quarter a year ago, actual revenue was $44.58MBased on 9 analysts’ estimates, the company’s revenue will be $83.69M in the next fiscal year. The high estimate is $175M and the low estimate is $12.77M.
